Study findings show the novel GPRC5D-targeting T-cell redirecting bispecific antibody, talquetamab, demonstrates substantial activity against MM cell lines and primary MM cells.
Study findings show the novel GPRC5D-targeting T-cell redirecting bispecific antibody, talquetamab, demonstrates substantial activity against MM cell lines and primary MM cells.
Study findings show the novel...